The immune systems of people with chronic fatigue syndrome differ from those of healthy people, and patients with recent diagnoses can be distinguished from those who have had the condition for longer, according to researchers.
The immune systems of people with chronic fatigue syndrome differ from those of healthy people, and patients with recent diagnoses can be distinguished from those who have had the condition for longer, researchers reported on Friday.
The findings do not have immediate clinical applications for patients, experts said. But the biomarkers discovered by the scientists may eventually form the basis of the first diagnostic test for the illness.
“A biomarker has been the goal for much of the research for the last 15 years, so it’s really excellent that they have found something they consider significant,” said Birgitta Evengard, MD, a professor of clinical microbiology at Umea University in Sweden and an expert on the illness.
Read more: http://nyti.ms/1EWBaUH
Source: The New York Times
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More